Natco Pharma has launched a generic version of Posaconazole Injection, 300 mg/16.70 ml, under its brand ‘Posanat’. This is the first time an injection version of this drug available in India. Posanat will be available in 18 mg/ml strength, a formulation for intravenous (IV) use. Posaconazole Injection is sold in the USA market by Merck under its brand name of ‘Noxafil’.
Posaconazole injection is an antifungal agent & used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
